The PD-1 inhibitor cemiplimab (Libtayo) significantly improved overall survival (OS) versus platinum-based chemotherapy as a frontline treatment for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and a PD-L1 expression level of at least 50%, meeting the primary end point of a phase 3 trial.1
Among 75 patients with metastatic CSCC, the ORR was 47% (95% CI, 35-59). The CR rate was 5% and the PR rate was 41%. The duration of response ranged from 3 months to over 15 months. Sixty percent of patients had a duration of response ≥6 months. In the 33 patients with locally advanced disease, the ORR was 49% (95% CI, 31-67), comprising all PRs. The duration of response ranged from 1 month to over 13 months. Sixty-three percent of patients had a duration of response ≥6 months.
- Phase 3 Trial Of Libtayo® (Cemiplimab) As Monotherapy For First-Line Advanced Non-Small Cell Lung Cancer Stopped Early Due To Highly Significant Improvement In Overall Survival. Published April 27, 2020. https://bit.ly/2KElhgE. Accessed April 27, 2020.
- FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma. Published September 28, 2018. https://bit.ly/2y2DzoX. Accessed April 27, 2020
... to read the full story